Nosocomial pneumonia (NP) is one of the most severe diseases associated with the hospital admission. It is commonly divided into two separate medical conditions: hospitalacquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Early identification of both conditions may be a challenge for clinicians due to lack of appropriate tests with required specificity and sensitivity. An article reviews the recent findings and the current status of inflammatory biomarkers in patients with HAP or VAP. We analyzed the potential application of biomarkers for the assessment of the risk of pneumonia, clinical outcomes and predicting of the response to the antibacterial therapy. The results of the pilot prospective clinical trial aimed to evaluate the sensitivity of different serum biomarkers in non-severe HAP in adults are presented.
Nosocтитутаomial pneumonia, diagnosis, biomarkres.